Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Cash (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Change in Cash for 10 consecutive years, with $17.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 36.5% year-over-year to $17.4 million, compared with a TTM value of -$27.7 million through Sep 2025, down 57.82%, and an annual FY2024 reading of -$23.4 million, up 28.47% over the prior year.
  • Change in Cash was $17.4 million for Q3 2025 at Spero Therapeutics, up from -$17.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $58.7 million in Q4 2022 and bottomed at -$40.5 million in Q1 2022.
  • Average Change in Cash over 5 years is -$1.9 million, with a median of -$5.5 million recorded in 2021.
  • The sharpest move saw Change in Cash plummeted 659.75% in 2021, then skyrocketed 21431.27% in 2022.
  • Year by year, Change in Cash stood at -$275000.0 in 2021, then surged by 21431.27% to $58.7 million in 2022, then tumbled by 129.82% to -$17.5 million in 2023, then plummeted by 33.78% to -$23.4 million in 2024, then skyrocketed by 174.45% to $17.4 million in 2025.
  • Business Quant data shows Change in Cash for SPRO at $17.4 million in Q3 2025, -$17.7 million in Q2 2025, and -$4.0 million in Q1 2025.